GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anavex Life Sciences Corp (NAS:AVXL) » Definitions » General and Admin. Expense

AVXL (Anavex Life Sciences) General and Admin. Expense : $10.85 Mil (TTM As of Jun. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Anavex Life Sciences General and Admin. Expense?

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. Anavex Life Sciences's General and Admin. Expense for the three months ended in Jun. 2024 was $2.86 Mil. Its General and Admin. Expense for the trailing twelve months (TTM) ended in Jun. 2024 was $10.85 Mil.

Anavex Life Sciences General and Admin. Expense Historical Data

The historical data trend for Anavex Life Sciences's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anavex Life Sciences General and Admin. Expense Chart

Anavex Life Sciences Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
General and Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.85 5.86 9.02 13.07 12.04

Anavex Life Sciences Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
General and Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.25 2.59 2.61 2.79 2.86

Anavex Life Sciences General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

General and Admin. Expense for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $10.85 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anavex Life Sciences General and Admin. Expense Related Terms

Thank you for viewing the detailed overview of Anavex Life Sciences's General and Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Anavex Life Sciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anavex Life Sciences Corp (NAS:AVXL) » Definitions » General and Admin. Expense
Comparable Companies
SLNCF ERAS AUTL PRTA CDMO PLRX RLAY CRGX TYRA MRVI VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
0HFR:UK 12X1:Germany 12X1:Germany
Address
630 5th Avenue, 20th Floor, New York, NY, USA, 10111
Website
https://www.anavex.com
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.
Executives
Donhauser Peter D.o. director REGINA-KIRCHMAIER STRASSE 4, KAUFBEUREN 2M 87600
Steffen Thomas director FALLMERAYER STR. 19, MUNICH 2M 80796
Christopher U Missling director, officer: President, CEO, CFO, Treasurer, other: Secretary 61 MOULTON ST, CAMBRIDGE MA 02138
Athanasios Skarpelos 10 percent owner 14,RUE KLEBERG, GENEVA V8 CH-1201
Jiong Ma director 445 PARK AVENUE, 9TH FLOOR, NEW YORK NY 10022
Elliot Favus director 51 W 52ND STREET, 7TH FLOOR, NEW YORK NY 10091
Sandra Boenisch officer: PFO & Treasurer 51 WEST 52ND STREET, 7TH FLOOR, NEW YORK NY 10019
Claus Vander Velden director PO BOX MUENSTEREIFELER ST., COLOGNE 2M 50937
Bernd Metzner director 51 W 52ND STREET, 7TH FLOOR, NEW YORK NY 10019
George F Tidmarsh director, officer: Executive Director
John Robert Chisholm director 16308 36A AVENUE, SURREY A1 V3S 0X5
William Sean Lowry director 1172 BAY STREET, SUITE 300, ONTARIO Z4 M5S1L9
David L. Tousley director 14610 PAWNEE LANE, LEAWOOD KS 66224
Harvey Lalach director, officer: President CEO CFO 4837 CANYON RIDGE CRESENT, KELOWNA A1 V1W 4A1
Alison E. Ayers director 27 O'CONNOR CIRCLE, WEST ORANGE NJ 07052